Document Detail


The latest generation of beta-blockers: new pharmacologic properties.
MedLine Citation:
PMID:  16884657     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
beta-Blockers have generally demonstrated smaller reductions in cardiovascular events, compared with other antihypertensive classes, despite similar reductions in blood pressure. This may be due to the ineffectiveness of traditional beta-blockers, such as atenolol, in reducing central aortic pressure, a strong, independent predictor of cardiovascular outcome. However, the beta-blocker class is heterogeneous, and some newer beta-blockers, which exhibit vasodilatory effects independent of beta-blockade, provide beneficial effects on arterial stiffness and endothelial dysfunction, which may lead to reductions in central aortic pressure and improvements in clinical outcomes. For example, the vasodilating beta-blocker nebivolol was shown to improve forearm blood flow and arterial stiffness and, in a large clinical study, to significantly reduce morbidity and mortality, independent of left ventricular ejection fraction, among patients with chronic heart failure. Further research is warranted to investigate any potential differences between traditional and newer vasodilating beta-blockers on cardiovascular outcomes.
Authors:
Michala E Pedersen; John R Cockcroft
Related Documents :
25117597 - Use of a coverlet system for the management of skin microclimate.
8874987 - Systemic side effects of topical beta-adrenergic blockers.
7295917 - Effects of treatment on circadian rhythms of blood pressure.
22574537 - Correlation between left atrial volume index and pulmonary artery pressure in patients ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current hypertension reports     Volume:  8     ISSN:  1522-6417     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-03     Completed Date:  2006-12-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  279-86     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK. cockcroftjr@cf.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology*,  therapeutic use
Blood Pressure / drug effects
Cardiovascular Diseases / drug therapy,  physiopathology
Coronary Circulation / drug effects
Endothelium, Vascular / drug effects,  physiopathology
Forearm / blood supply
Humans
Regional Blood Flow / drug effects
Stroke Volume / drug effects
Vasodilator Agents / pharmacology
Ventricular Function, Left / drug effects
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Vasodilator Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A self-destruction game.
Next Document:  Monitoring vascular health beyond blood pressure.